OBJECTIVE: To explore the role of immune cells in anti-RNP autoimmunity in a murine model of pneumonitis or glomerulonephritis, using adoptive transfer techniques. METHODS: Donor mice were immunized with 50 mug of U1-70-kd small nuclear RNP fusion protein and 50 mug of U1 RNA adjuvant. Whole splenocytes as well as CD4+ cell and dendritic cell (DC) subsets from the immunized mice were infused into naive syngeneic recipients. Anti-RNP and T cell responses were assessed by immunoblotting, enzyme-linked immunosorbent assay, and flow cytometry. Development of renal or lung disease was assessed by histology and urinalysis. RESULTS: Unfractionated splenocytes from donor mice without proteinuria induced predominantly lung disease in recipients (8 [57%] of 14 versus 2 [14%] of 14 developing renal disease; P = 0.046). However, infusion of CD4+ cells from donors without proteinuria induced renal disease more frequently than lung disease (7 [70%] of 10 versus 2 [20%] of 10; P = 0.01); adoptive transfer of RNP+CD4+ T cells from short-term culture yielded similar results (renal disease in 8 [73%] of 11 recipients versus lung disease in 3 [27%] of 11). Cotransfer of splenic myeloid DCs and CD4+ T cells from immunized donors prevented induction of renal disease in all 5 recipients (P = 0.026 versus recipients of fresh CD4+ cells alone), although lung disease was still observed in 1 of 5 mice. Transfer of myeloid DCs alone from immunized donors induced lung disease in 3 (60%) of 5 recipients, without evidence of nephritis. Cotransfer of splenocytes from mice with and those without nephritis led to renal disease in 4 of 5 recipients, without evidence of lung disease. CONCLUSION: These findings indicate that RNP+CD4+ T cells are sufficient to induce anti-RNP autoimmunity, tissue targeting in anti-RNP autoimmunity can be deviated to either a renal or pulmonary phenotype depending on the presence of accessory cells such as myeloid DCs, and DC subsets can play a role in both propagation of autoimmunity and end-organ targeting.
OBJECTIVE: To explore the role of immune cells in anti-RNPautoimmunity in a murine model of pneumonitis or glomerulonephritis, using adoptive transfer techniques. METHODS:Donormice were immunized with 50 mug of U1-70-kd small nuclear RNP fusion protein and 50 mug of U1 RNA adjuvant. Whole splenocytes as well as CD4+ cell and dendritic cell (DC) subsets from the immunized mice were infused into naive syngeneic recipients. Anti-RNP and T cell responses were assessed by immunoblotting, enzyme-linked immunosorbent assay, and flow cytometry. Development of renal or lung disease was assessed by histology and urinalysis. RESULTS: Unfractionated splenocytes from donormice without proteinuria induced predominantly lung disease in recipients (8 [57%] of 14 versus 2 [14%] of 14 developing renal disease; P = 0.046). However, infusion of CD4+ cells from donors without proteinuria induced renal disease more frequently than lung disease (7 [70%] of 10 versus 2 [20%] of 10; P = 0.01); adoptive transfer of RNP+CD4+ T cells from short-term culture yielded similar results (renal disease in 8 [73%] of 11 recipients versus lung disease in 3 [27%] of 11). Cotransfer of splenic myeloid DCs and CD4+ T cells from immunized donors prevented induction of renal disease in all 5 recipients (P = 0.026 versus recipients of fresh CD4+ cells alone), although lung disease was still observed in 1 of 5 mice. Transfer of myeloid DCs alone from immunized donors induced lung disease in 3 (60%) of 5 recipients, without evidence of nephritis. Cotransfer of splenocytes from mice with and those without nephritis led to renal disease in 4 of 5 recipients, without evidence of lung disease. CONCLUSION: These findings indicate that RNP+CD4+ T cells are sufficient to induce anti-RNPautoimmunity, tissue targeting in anti-RNPautoimmunity can be deviated to either a renal or pulmonary phenotype depending on the presence of accessory cells such as myeloid DCs, and DC subsets can play a role in both propagation of autoimmunity and end-organ targeting.
Authors: Sean R Christensen; Jonathan Shupe; Kevin Nickerson; Michael Kashgarian; Richard A Flavell; Mark J Shlomchik Journal: Immunity Date: 2006-09 Impact factor: 31.745
Authors: Ingel K Demedts; Ken R Bracke; Tania Maes; Guy F Joos; Guy G Brusselle Journal: Am J Respir Cell Mol Biol Date: 2006-04-20 Impact factor: 6.914
Authors: E Bodolay; Z Szekanecz; K Dévényi; L Galuska; I Csípo; J Vègh; I Garai; G Szegedi Journal: Rheumatology (Oxford) Date: 2005-02-16 Impact factor: 7.580
Authors: Brian D Rudd; Jetse J Smit; Richard A Flavell; Lena Alexopoulou; Matthew A Schaller; Achim Gruber; Aaron A Berlin; Nicholas W Lukacs Journal: J Immunol Date: 2006-02-01 Impact factor: 5.422
Authors: Eric L Greidinger; YunJuan Zang; Kimberly Jaimes; Scott Hogenmiller; Mehdi Nassiri; Pablo Bejarano; Glen N Barber; Robert W Hoffman Journal: Arthritis Rheum Date: 2006-02
Authors: M F Carpintero; L Martinez; I Fernandez; A C Garza Romero; C Mejia; Y J Zang; R W Hoffman; E L Greidinger Journal: Lupus Date: 2015-03-02 Impact factor: 2.911
Authors: D P Ascherman; Y Zang; I Fernandez; E S Clark; W N Khan; L Martinez; E L Greidinger Journal: Arthritis Rheumatol Date: 2018-07-25 Impact factor: 10.995